SLIMOGIC 2.5mg Orforglipron Tablets

INDICATIONS

SLIMIOGIC ™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.

LIMITATION OF USE

Concomitant use with another GLP-1 receptor agonist is not recommended. 

WARNINGS AND PRECAUTIONS
Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Acute Pancreatitis

Has been observed in patients treated with GLP-1 receptor agonists, including SLIMIOGIC. Discontinue if pancreatitis is suspected.

Gastrointestinal effects

Use has been associated with gastrointestinal adverse reactions, sometimes severe. SLIMIOGIC is not recommended in patients with severe gastroparesis.

Acute Kidney Injury Due to Volume Depletion

Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.

Hypoglycemia

Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dosage of insulin or insulin secretagogue may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

Hypersensitivity Reactions

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If suspected, advise the patient to promptly seek medical attention and discontinue SLIMIOGIC.

Diabetic Retinopathy Complications in Patients with Type 2 Diabetes

Has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Monitor patients with a history of diabetic retinopathy for progression.

Acute Gallbladder Disease: Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated.

Pulmonary Aspiration During General Anesthesia and Deep Sedation

Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures.  

DOSAGE AND ADMINISTRATION

Take SLIMIOGIC orally once daily, with or without food.

Swallow tablets whole. Do not break, crush, or chew.

Do not take more than one tablet per day.
 

OVERDOSE
In the event of an overdose, consider contacting Poison Control or a medical toxicologist for latest recommendations. Initiate appropriate supportive treatment according to the patient's clinical signs and symptoms. A period of observation and supportive treatment may be necessary, considering the half-life of orforglipron.

PRESENTATION
1 blister strips of 10 tablets are packed in a printed carton along with a leaflet.
 

STORAGE

Store in the original blister package in order to protect from light and moisture.

Store below 30℃.
 

SHELF LIFE

Expiry date is stated on the carton.